CytoSorbents (NASDAQ:CTSO) has received a research grant from a division of the NIH to test the ability of its existing polymers to remove cytokines and lipopolysaccharide (LPS) endotoxin from septic porcine plasma, a...
The European Union approved CytoSorbents‘ (NASDAQ:CTSO) CytoSorb blood purification technology for the removal of rivaroxaban during cardiothoracic surgery requiring cardiopulmonary bypass. Rivaroxaban is a...
The FDA granted breakthrough therapy designation to CytoSorbents‘ (NASDAQ:CTSO) CytoSorb blood purification technology for the removal of ticagrelor during emergency surgery. Ticagrelor is an antiplatelet drug...